skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers

Abstract

Molecular imaging agents have the ability to non-invasively visualize, characterize, and quantify the molecular biology of disease. Recent advances in nuclear probe development, particularly in PET radiotracers, have generated many new imaging agents with precise molecular targets. With such specificity, PET probes may be utilized as biomarkers to objectively interrogate and evaluate pathology. Whereas the current indications for PET imaging are predominately confined to staging and restaging of malignancy, the utility of PET greatly expands when utilized as a biomarker, the topic of this review. As an imaging biomarker, PET may be used to (1) measure target expression to select subsets of patients who would most benefit from targeted therapy; (2) measure early treatment response to predict therapeutic efficacy; and (3) relate tumor response to survival. This work will discuss the application of radiotracers to targeted cancer therapy. Particular attention is given to new radiotracers evaluated in recently completed clinical trials and those with current or potential clinical utility. The diverse roles of PET in clinical trails for drug development are also examined.

Authors:
ORCiD logo [1];  [1]
  1. Univ. of Pennsylvania, Philadelphia, PA (United States). Perelman School of Medicine, Dept. of Radiology and Division of Nuclear Medicine and Molecular Imaging
Publication Date:
Research Org.:
Univ. of Pennsylvania, Philadelphia, PA (United States)
Sponsoring Org.:
USDOE; Susan G. Komen Foundation; National Institutes of Health (NIH)
OSTI Identifier:
1462353
Alternate Identifier(s):
OSTI ID: 1414471
Grant/Contract Number:  
SC0012476; AC140060; U01-CA19025; U01-CA148131
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Cancer Letters
Additional Journal Information:
Journal Volume: 387; Journal Issue: C; Journal ID: ISSN 0304-3835
Publisher:
Elsevier
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; Cancer biomarkers; Positron emission tomography; Clinical trials

Citation Formats

Pantel, Austin R., and Mankoff, David A.. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. United States: N. p., 2016. Web. doi:10.1016/j.canlet.2016.05.008.
Pantel, Austin R., & Mankoff, David A.. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. United States. doi:10.1016/j.canlet.2016.05.008.
Pantel, Austin R., and Mankoff, David A.. Mon . "Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers". United States. doi:10.1016/j.canlet.2016.05.008. https://www.osti.gov/servlets/purl/1462353.
@article{osti_1462353,
title = {Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers},
author = {Pantel, Austin R. and Mankoff, David A.},
abstractNote = {Molecular imaging agents have the ability to non-invasively visualize, characterize, and quantify the molecular biology of disease. Recent advances in nuclear probe development, particularly in PET radiotracers, have generated many new imaging agents with precise molecular targets. With such specificity, PET probes may be utilized as biomarkers to objectively interrogate and evaluate pathology. Whereas the current indications for PET imaging are predominately confined to staging and restaging of malignancy, the utility of PET greatly expands when utilized as a biomarker, the topic of this review. As an imaging biomarker, PET may be used to (1) measure target expression to select subsets of patients who would most benefit from targeted therapy; (2) measure early treatment response to predict therapeutic efficacy; and (3) relate tumor response to survival. This work will discuss the application of radiotracers to targeted cancer therapy. Particular attention is given to new radiotracers evaluated in recently completed clinical trials and those with current or potential clinical utility. The diverse roles of PET in clinical trails for drug development are also examined.},
doi = {10.1016/j.canlet.2016.05.008},
journal = {Cancer Letters},
number = C,
volume = 387,
place = {United States},
year = {Mon May 16 00:00:00 EDT 2016},
month = {Mon May 16 00:00:00 EDT 2016}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 3 works
Citation information provided by
Web of Science

Save / Share: